{"id":57573,"date":"2024-02-27T17:50:34","date_gmt":"2024-02-27T17:50:34","guid":{"rendered":"https:\/\/medsname.com\/hydrosar\/"},"modified":"2026-04-30T10:24:24","modified_gmt":"2026-04-30T10:24:24","slug":"hydrosar","status":"publish","type":"product","link":"https:\/\/medsbase.com\/nl\/hydrosar\/","title":{"rendered":"Hydrosar"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Hydrosar?<\/h3>\n<p style=\"margin:0;\"><strong>Hydrosar<\/strong> is an oral capsule from Sarabhai Chemicals containing <strong>hydroxyurea (hydroxycarbamide) 500 mg<\/strong> &mdash; a ribonucleotide reductase inhibitor used for <strong>chronic myeloid leukaemia, polycythaemia vera, essential thrombocythaemia, sickle cell disease<\/strong>, and several solid tumours (head &amp; neck, melanoma). Standard adult dosing varies by indication: typically <strong>15&ndash;30 mg\/kg\/day<\/strong> in haematology; <strong>20&ndash;35 mg\/kg\/day<\/strong> in sickle cell. Mandatory monitoring: <strong>FBC every 2 weeks initially, then monthly<\/strong> &mdash; titrate to ANC &gt; 2,000\/&micro;L and platelets &gt; 100,000\/&micro;L. Pregnancy contraindication; reliable contraception in both sexes throughout treatment. Long-term concern: leg ulcers (chronic, painful), squamous cell skin cancers, possible secondary leukaemia (controversial, mainly in long-term polycythaemia vera).<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Wat u krijgt bij MedsBase:<\/strong> WHO-GMP gecertificeerde fabrikant \u00b7 Discrete verpakking \u00b7 Wereldwijde verzending \u00b7 1.400+ geverifieerde <a href=\"https:\/\/medsbase.com\/nl\/reviews\/\">klantbeoordelingen<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Elke bestelling is gedekt door onze <a href=\"https:\/\/medsbase.com\/nl\/medsbase-re-shipment-assurance-policy\/\"><strong>Reshipment Assurance Policy<\/strong><\/a> \u2014 als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Specialistisch toezicht vereist.<\/strong> Kankermedicatie moet worden voorgeschreven door een behandelend oncoloog met een bevestigde diagnose, baseline-stadi\u00ebring en een gedefinieerd behandelplan. Start, stop, wijzig de dosis of gebruik kankermedicatie nooit buiten een door oncologie geleid zorgplan. De meeste kankermedicijnen vereisen regelmatige bloedtestmonitoring (FBC, LFT, nierfunctie), zijn absoluut gecontra-indiceerd tijdens zwangerschap en hebben significante geneesmiddelinteracties.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Versleutelde Afrekenprocedure<\/strong> \u00b7 <strong>\ud83d\udcb3 Geverifieerde Betaalprocessor<\/strong> \u00b7 <strong>\ud83d\ude9a Wereldwijde Verzending<\/strong> \u00b7 <strong>\u2b50 4.9\/5 van 1.400+ klanten<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">What Is Hydrosar?<\/h2>\n<p>Hydrosar is an oral capsule from Sarabhai Chemicals containing <strong>hydroxyurea 500 mg<\/strong> (also called hydroxycarbamide). Hydroxyurea inhibits ribonucleotide reductase, blocking DNA synthesis. It is one of the most widely-used and longest-established cytoreductive agents, with a 60-year clinical safety record across haematological malignancies, sickle cell disease and several solid tumours.<\/p>\n<h2 class=\"wp-block-heading\">Toepassingen en Indicaties<\/h2>\n<ul>\n<li><strong>Chronic myeloid leukaemia<\/strong> &mdash; cytoreduction at diagnosis or as alternative when TKIs (imatinib etc) cannot be used<\/li>\n<li><strong>Polycythaemia vera<\/strong> &mdash; first-line cytoreduction in high-risk disease<\/li>\n<li><strong>Essential thrombocythaemia<\/strong> &mdash; first-line cytoreduction in high-risk disease<\/li>\n<li><strong>Myelofibrosis (early phase)<\/strong> &mdash; symptom and counts control<\/li>\n<li><strong>Sickle cell disease<\/strong> &mdash; reduces frequency of vaso-occlusive crises and acute chest syndrome; raises HbF<\/li>\n<li><strong>Acute leukaemia &mdash; emergency leukocytosis<\/strong> reduction (rapid cytoreduction before definitive therapy)<\/li>\n<li><strong>Head and neck squamous cell carcinoma<\/strong> &mdash; with concurrent radiotherapy (older regimens)<\/li>\n<li><strong>Melanoma, ovarian cancer (limited modern use)<\/strong><\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Dosering en wijze van inname<\/h2>\n<p>Dose varies by indication. Examples for adults:<\/p>\n<ul>\n<li><strong>CML, ET, PV cytoreduction:<\/strong> start 15 mg\/kg\/day; titrate to 15&ndash;30 mg\/kg\/day based on counts<\/li>\n<li><strong>Sickle cell disease:<\/strong> start 15 mg\/kg\/day; increase by 5 mg\/kg\/day every 8 weeks to maximum 35 mg\/kg\/day or maximal tolerated dose<\/li>\n<li><strong>Acute leukaemia emergency cytoreduction:<\/strong> 50&ndash;100 mg\/kg\/day for 1&ndash;2 days (specialist)<\/li>\n<\/ul>\n<ol>\n<li>Take once or twice daily as prescribed, with or without food.<\/li>\n<li>Slik de capsules heel door. <strong>Do NOT open capsules<\/strong> &mdash; the powder is cytotoxic and harmful on contact. If a capsule cannot be swallowed, the contents can be dispersed in water with caregiver wearing gloves and avoiding skin\/eye contact.<\/li>\n<li><strong>Verplichte monitoring:<\/strong> FBC every 2 weeks initially (or weekly during titration in sickle cell), then monthly. U&#038;E + LFTs every 1&ndash;3 months. Reticulocyte count, HbF (sickle cell). MCV rises on hydroxyurea (a useful marker of compliance).<\/li>\n<li>Dose adjustments based on counts: hold for ANC &lt; 2,000\/&micro;L, platelets &lt; 80,000\/&micro;L, or Hb &lt; 4.5 g\/dL. Resume at lower dose once recovered.<\/li>\n<li>Folic acid 5 mg daily often co-prescribed (especially in haemoglobinopathy).<\/li>\n<li>Drink plenty of fluids to reduce risk of hyperuricaemia and tumour lysis syndrome.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Bijwerkingen<\/h2>\n<p><strong>Vaak voorkomend:<\/strong> myelosuppression (the desired effect at therapeutic dose), nausea, anorexia, mucositis, mild diarrhoea, skin hyperpigmentation, nail pigmentation, hair thinning.<\/p>\n<p><strong>Belangrijk:<\/strong><\/p>\n<ul>\n<li><strong>Leg ulcers<\/strong> &mdash; chronic, painful, slow-healing; affects ~5% of long-term users; may require dose reduction or discontinuation<\/li>\n<li><strong>Squamous cell skin cancers<\/strong> &mdash; long-term users, especially fair-skinned; annual dermatology review and rigorous SPF use<\/li>\n<li>Macrocytosis (raised MCV) &mdash; expected, marker of compliance, not a problem<\/li>\n<li>Pulmonary fibrosis (rare)<\/li>\n<li>Hyperuricaemia, gout<\/li>\n<li>Possible secondary leukaemia in long-term polycythaemia vera (controversial)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Waarschuwingen<\/h2>\n<ul>\n<li><strong>Zwangerschap:<\/strong> teratogenic. Strong contraception throughout treatment AND for 6 months after the last dose, in BOTH male and female patients.<\/li>\n<li><strong>Borstvoeding:<\/strong> excreted in breast milk &mdash; avoid.<\/li>\n<li><strong>Nierfunctiestoornis:<\/strong> reduce dose for eGFR &lt; 60 mL\/min.<\/li>\n<li><strong>Ernstige leverfunctiestoornis:<\/strong> caution.<\/li>\n<li><strong>Skin cancer screening:<\/strong> annual dermatology review for long-term users; rigorous daily SPF.<\/li>\n<li><strong>Vaccinaties:<\/strong> live vaccines contraindicated; inactivated vaccines safe and recommended.<\/li>\n<li><strong>HIV co-infection:<\/strong> hydroxyurea + didanosine combination has caused fatal pancreatitis &mdash; avoid.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Geneesmiddelinteracties<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combineren met<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Effect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Wat te doen<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Didanosine (HIV antiretroviral)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Fatal pancreatitis reported<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Absolutely avoid combination.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Other myelosuppressive drugs (chemotherapy, immunosuppressants)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Additive marrow suppression<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Specialist supervision; close FBC monitoring.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Levende vaccins<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Risico op verspreide infectie<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Gecontra-indiceerd.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Allopurinol or febuxostat<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Useful for hyperuricaemia \/ gout from cell turnover<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Vaak gecombineerd voorgeschreven.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Opslag<\/h2>\n<ul>\n<li>Room temperature, 15&ndash;30&deg;C, original blister.<\/li>\n<li>Keep out of reach of children, women of childbearing potential, pets.<\/li>\n<li>Caregivers handling broken capsules should wear gloves &mdash; powder is cytotoxic.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Gerelateerde alternatieven op MedsBase<\/h2>\n<p>Andere oncologische medicijnen die naast dit product wordt aangeboden:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/ondrea\/\"><strong>Ondrea (hydroxyurea 500 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/riborea\/\"><strong>Riborea (hydroxyurea 500 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/nl\/anti-cancer-medication\/\">Bekijk alle anti-kankermedicijnen \u2192<\/a><\/p>\n<h2 id=\"faqs\">Veelgestelde vragen<\/h2>\n<h3 class=\"wp-block-heading\">How does Hydrosar help in sickle cell disease?<\/h3>\n<p>Hydroxyurea is the most important disease-modifying drug for sickle cell. It raises fetal haemoglobin (HbF) levels, which prevents red cells from sickling. Effects: <strong>~50% reduction in vaso-occlusive crises, fewer hospitalisations, less acute chest syndrome, lower blood transfusion requirement, improved survival<\/strong>. Most patients see clinical benefit at 8&ndash;12 weeks of dose titration; full benefit at 6&ndash;12 months. Underused worldwide despite a strong evidence base &mdash; talk to your haematologist if you have sickle cell and have not been offered hydroxyurea.<\/p>\n<h3 class=\"wp-block-heading\">What blood tests do I need on Hydrosar?<\/h3>\n<p><strong>Verplicht:<\/strong> FBC every 2 weeks initially (weekly during sickle cell titration), then monthly once stable. U&#038;E + LFTs every 1&ndash;3 months. Sickle cell patients also: HbF measurement, reticulocyte count. Hold or reduce dose for ANC &lt; 2,000\/&micro;L, platelets &lt; 80,000\/&micro;L, or Hb &lt; 4.5 g\/dL.<\/p>\n<h3 class=\"wp-block-heading\">Why is Hydrosar associated with leg ulcers?<\/h3>\n<p>Chronic, painful leg ulcers affect ~5% of long-term hydroxyurea users, mostly around the malleolus (ankle). Mechanism is unclear (probably microvascular). They are slow to heal and may require dose reduction or hydroxyurea discontinuation. Tell your doctor immediately if you develop a leg ulcer on hydroxyurea &mdash; do not delay.<\/p>\n<h3 class=\"wp-block-heading\">Will Hydrosar cause cancer?<\/h3>\n<p>Long-term hydroxyurea use slightly increases the risk of <strong>squamous cell skin cancers<\/strong>, especially in fair-skinned patients. Annual full-skin dermatology review, daily broad-spectrum SPF, sun avoidance. The historic concern about <strong>secondary leukaemia in polycythaemia vera<\/strong> on long-term hydroxyurea is debated &mdash; large modern data suggest the risk is low and that PV itself carries an inherent leukaemic transformation risk.<\/p>\n<h3 class=\"wp-block-heading\">Can I get pregnant on Hydrosar?<\/h3>\n<p>Hydroxyurea is teratogenic. Reliable contraception is mandatory throughout treatment AND for at least <strong>6 months after the last dose, in both male and female patients<\/strong>. Discuss family planning with your haematologist before starting. In sickle cell, hydroxyurea is sometimes held during planned pregnancy with close monitoring.<\/p>\n<h3 class=\"wp-block-heading\">Why does my MCV go up on Hydrosar?<\/h3>\n<p>Macrocytosis (raised MCV) is an expected and useful effect &mdash; it indicates you are taking the drug consistently. Doctors use MCV as a compliance marker in sickle cell. The rise is benign and not associated with any clinical problem.<\/p>\n<h3 class=\"wp-block-heading\">Can I open a capsule if I cannot swallow it?<\/h3>\n<p>Best avoided &mdash; the powder is cytotoxic and harmful on skin, eye and respiratory contact. If essential, the caregiver must wear gloves, work in a ventilated area, and disperse the contents in a small amount of water for the patient to drink immediately. Wash hands and surfaces afterwards. Specialist pharmacist can prepare a liquid suspension as an alternative.<\/p>\n<h3 class=\"wp-block-heading\">Can I take Hydrosar with HIV antiretrovirals?<\/h3>\n<p>Most ART is compatible. The dangerous combination is <strong>hydroxyurea + didanosine<\/strong>, which has caused fatal pancreatitis. Tell every prescriber about both medications and ensure no didanosine is in your regimen.<\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>Waarom bestellen bij MedsBase<\/h3>\n<p>Elke batch wordt ingekocht bij een <strong>WHO-GMP gecertificeerde fabrikant<\/strong>. Bestellingen worden verzonden in eenvoudige, ongemarkeerde verpakkingen door onze logistieke partners en vallen onder onze <a href=\"\/nl\/medsbase-re-shipment-assurance-policy\/\">Reshipment Assurance Policy<\/a>: als een pakket niet binnen 20 werkdagen arriveert, sturen wij kosteloos een nieuwe zending, zonder vragen te stellen.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Gerelateerde Antikankermedicijnen<\/h3>\n<p>Andere oncologische medicijnen die naast dit product wordt aangeboden:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/nl\/ondrea\/\">Ondrea (hydroxyurea 500 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/endoxan\/\">Endoxan (cyclofosfamide 50 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/imatib\/\">Imatib (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/veenat\/\">Veenat (imatinib 100\/400 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/nl\/folitrax\/\">Folitrax (methotrexaat 2,5\/7,5\/10 mg)<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Manages sickle cell anemia<br \/>\n\u2705 Reduces frequency of painful crises<br \/>\n\u2705 Controls blood cell production<br \/>\n\u2705 Prevents clot formation<br \/>\n\u2705 Lowers risk of stroke<\/p>\n<p>Hydrosar contains Hydroxyurea.<\/p>","protected":false},"featured_media":57574,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223],"product_tag":[4331,4315],"class_list":{"0":"post-57573","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_tag-hydrosar","10":"product_tag-hydroxyurea","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product\/57573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/comments?post=57573"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media\/57574"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/media?parent=57573"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_brand?post=57573"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_cat?post=57573"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/nl\/wp-json\/wp\/v2\/product_tag?post=57573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}